W M McCORMACK1, M P Seiler1,2, T K Bertin1, K Ubhayakar1, D J Palmer1, P Ng1, T C Nichols3, B Lee1,4. 1. Department of Molecular and Human Genetics. 2. Interdepartmental Program in Cell and Molecular Biology, Baylor College of Medicine, Houston, TX. 3. Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC. 4. The Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Adenoviral vector-mediated gene therapy might have potential for long-term correction of the monogenic disease hemophilia A. OBJECTIVE: In this study, we tested the efficacy of administering a helper-dependent adenoviral vector (HDV) designed for maximal liver-restricted canine factor VIII (cFVIII) expression on three out-bred hemophilia A dogs. METHODS: Three FVIII-deficient animals from the University of North Carolina colony were injected with 1 x 10(12) (Dog A), and 3 x 10(12) (Dog B and C) vp kg(-1) helper-dependent adenoviral vector, and we performed systematic analysis of toxicity, persistence of therapeutic gene expression, and molecular analysis of gene transfer. RESULTS: We observed acute dose-dependent elevation in liver enzymes and thrombocytopenia after injection, although both were transient and resolved within 2 weeks. The whole blood clotting time (WBCT), plasma FVIII concentration, FVIII activity, and activated partial thromboplastin time in all animals improved significantly after treatment, and two animals receiving a higher dose reached near normal WBCT with low-level FVIII activity until terminal sacrifice at 3 months, and 2 years. Importantly, the treated dogs suffered no bleeding events after injection. Moreover, we observed persistent vector-specific DNA and RNA in liver tissue collected from one high-dose animal at days 18 and 79, and could not detect the formation of inhibitory antibodies. CONCLUSION: Although vector-associated toxicity remains an obstacle, a single injection of HDV led to long-term transgene expression and vector persistence in two FVIII-deficient animals with conversion of their severe phenotype to a moderate one.
BACKGROUND: Adenoviral vector-mediated gene therapy might have potential for long-term correction of the monogenic disease hemophilia A. OBJECTIVE: In this study, we tested the efficacy of administering a helper-dependent adenoviral vector (HDV) designed for maximal liver-restricted caninefactor VIII (cFVIII) expression on three out-bred hemophilia Adogs. METHODS: Three FVIII-deficient animals from the University of North Carolina colony were injected with 1 x 10(12) (Dog A), and 3 x 10(12) (Dog B and C) vp kg(-1) helper-dependent adenoviral vector, and we performed systematic analysis of toxicity, persistence of therapeutic gene expression, and molecular analysis of gene transfer. RESULTS: We observed acute dose-dependent elevation in liver enzymes and thrombocytopenia after injection, although both were transient and resolved within 2 weeks. The whole blood clotting time (WBCT), plasma FVIII concentration, FVIII activity, and activated partial thromboplastin time in all animals improved significantly after treatment, and two animals receiving a higher dose reached near normal WBCT with low-level FVIII activity until terminal sacrifice at 3 months, and 2 years. Importantly, the treated dogs suffered no bleeding events after injection. Moreover, we observed persistent vector-specific DNA and RNA in liver tissue collected from one high-dose animal at days 18 and 79, and could not detect the formation of inhibitory antibodies. CONCLUSION: Although vector-associated toxicity remains an obstacle, a single injection of HDV led to long-term transgene expression and vector persistence in two FVIII-deficient animals with conversion of their severe phenotype to a moderate one.
Authors: Nicola Brunetti-Pierri; Donna J Palmer; Viraj Mane; Milton Finegold; Arthur L Beaudet; Philip Ng Journal: Mol Ther Date: 2005-07 Impact factor: 11.454
Authors: Nicola Brunetti-Pierri; Timothy C Nichols; Stephanie McCorquodale; Elizabeth Merricks; Donna J Palmer; Arthur L Beaudet; Philip Ng Journal: Hum Gene Ther Date: 2005-07 Impact factor: 5.695
Authors: C R O'Riordan; A Lachapelle; C Delgado; V Parkes; S C Wadsworth; A E Smith; G E Francis Journal: Hum Gene Ther Date: 1999-05-20 Impact factor: 5.695
Authors: A M Gallo-Penn; P S Shirley; J L Andrews; S Tinlin; S Webster; C Cameron; C Hough; C Notley; D Lillicrap; M Kaleko; S Connelly Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: Lorenz Jager; Martin A Hausl; Christina Rauschhuber; Nicola M Wolf; Mark A Kay; Anja Ehrhardt Journal: Nat Protoc Date: 2009 Impact factor: 13.491
Authors: Nicola Brunetti-Pierri; Thomas Ng; David Iannitti; William Cioffi; Gary Stapleton; Mark Law; John Breinholt; Donna Palmer; Nathan Grove; Karen Rice; Cassondra Bauer; Milton Finegold; Arthur Beaudet; Charles Mullins; Philip Ng Journal: Hum Gene Ther Date: 2013-08 Impact factor: 5.695
Authors: Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High Journal: ILAR J Date: 2009
Authors: Denise E Sabatino; Christian Furlan Freguia; Raffaella Toso; Andrey Santos; Elizabeth P Merricks; Haig H Kazazian; Timothy C Nichols; Rodney M Camire; Valder R Arruda Journal: Blood Date: 2009-09-21 Impact factor: 22.113